Antibacterials and antifungal agents

Drug-Induced Liver Disease

Volumn , Issue , 2002, Pages 471-504

  Westphal, Jean Frederic ^a   Brogard, Jean Marie ^a  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 3142524747     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (271)

1. Sikuler E, Guetta V, Keynan A, Neumann L, Schlaeffer F. Abnormalities in bilirubin and liver enzyme levels in adult patients with bacteremia. Arch Intern Med 1989; 149:2246-2248.
2. Zimmerman HJ, Fang M, Utili R, Seef LB, Hoofnagle J. Jaundice due to bacterial infection. Gastroenterology 1979; 77:362-374.
3. Parry MF. The penicillins. Med Clin North Am 1987; 71:1093-1112.
4. Golstein LI, Ishak KG. Hepatic injury associated with penicillin therapy. Arch Pathol 1974; 98:114-117.
5. Onate J, Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, Gonzales de Zarate P, Aguirre C. Hepatotoxicity associated with penicillin V therapy. Clin Infect Dis 1995; 20:474-475.
6. Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91-year old woman. Dig Dis Sci 1981; 26:470-473.
7. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis, paucity of bile ducts, red cell aplasia and the Stevens-Johnson syndrome: an ampicillin-associated case. Gastroenterology 1990; 99:854-856.
8. Davies MH, Harrison RF, Elias E, Hubscher SG. Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol 1994; 20:12-116.
9. Anderson CS, Nicholis J, Rowland R, Labrooy JT. Hepatic granulomas: a 15-year experience in the Royal Adelaide Hospital. Med J Aust 1988; 148:71-74.
10. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996; 156:1327-1332.
11. Wilson FM, Belamaric J, Lauter CB, Lerner AM. Anicteric carbenicillin hepatitis: eight episodes in four patients. JAMA 1975; 232:818-821.
12. Lang R, Lishner M, Ravid M. Adverse reactions to prolonged treatment with high doses of carbenicillin and ureidopenicillins. Rev Infect Dis 1991; 13:68-72.
13. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin, and dicloxacillin. J Hepatol 1992; 15:154-161.
14. Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol 1997; 12(Suppl):S242-S250.
15. Derby LE, Jick HJ, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993; 158:596-600.
16. George DK, Crawford DH. Antibacterial-induced hepatotoxicity. Incidence, prevention, and management. Drug Safety 1996; 1:79-85.
17. Fairley CK, Mc Neil JJ, Desmond P, Smallwood R, Young H, Forbes A, Purcell P, Boyd I. Risk factors for development of flucloxacillin-associated jaundice. Br Med J 1993; 306: 233-235.
18. Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. Med J Aust 1989; 151:701-705.
19. Miros M, Welker N, Kerlin P, Harris O. Flucloxacillin-induced delayed cholestatic hepatitis. Aust NZ J Med 1990; 20:251-253.
20. Piotrowicz A, Polkey M, Wilkinson M. Ursodeoxycholic acid for the treatment of flucloxa-cillin-associated cholestasis. J Hepatol 1995; 22:119-121.
21. Dismukes WE. Oxacillin-induced hepatic dysfunction. JAMA 1973; 226:861-863.
22. Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. Ann Intern Med 1978; 89:497-500.
23. Bruckstein AH, Attia AA. Oxacillin hepatitis: two patients with liver biopsy, and review of the literature. Am J Med 1978; 64:519-522.
24. Tauris P, Jorgensen NF, Petersen CM, Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives: a report of two cases. Acta Med Scand 1985; 217:567-569.
25. Pollock AA, Berger SA, Simberkoff MS, Rahall JJ. Hepatitis associated with high dose oxacillin therapy. Arch Intern Med 1978; 138:915-917.
26. Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillin-sodium therapy. J Clin Gastroenterol 1986; 8:77-78.
27. Konikoff F, Alcalay J, Halevy J. Cloxacillin-induced cholestatic jaundice. Am J Gastroenterol 1986; 81:1082-1083.
28. Aderka D, Livni E, Salamon F, Weinberger A, Pinkhas J. Use of macrophage inhibition factor and mast-cell degranulation tests for diagnosis of cloxacillin-induced cholestasis. Am J Gastroenterol 1986; 81:1084-1086.
29. Victorino RM, Maria VA, Correia AP, Moura C. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. Arch Intern Med 1987; 147:987-989.
30. Dowsett JF, Gillow T, Heagerty A, Radcliffe M, Toadi R, Isle I, Russell RC. Amoxycillin/clavulanic acid (Augmentin)-induced intrahepatic cholestasis. Dig Dis Sci 1989; 34:1290-1293.
31. Stricker BH, Van der Broek JW, Keuning J, Eberhardt W, Houben HG, Johnson M, Blok AP. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (Augmentin). Dig Dis Sci 1989; 34:1576-1580.
32. Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology 1989; 96:1135-1141.
33. Schneider JE, Kleinman MS, Kupiec JW. Cholestatic hepatitis after therapy with amoxicillin/clavulanate potassium. NY State J Med 1989; 89:355-356.
34. Verhamme M, Ramboer C, Vanderbruaene P, Inderadjaja N. Cholestatic hepatitis due to an amoxicillin-clavulanic preparation. J Hepatol 1989; 9:260-264.
35. Michielsen PP, Vanoutryve MJ, Vanmarck EA, Demaeyer MH, Pelckmans PA, Vanmaercke YM. Amoxycillin/clavulanic acid-induced cholestasis. J Hepatol 1990; 11:392.
36. Wong FS, Ryan J, Dabkowski P, Dudley FJ, Sewell RB, Smallwood RA. Augmentin-induced jaundice. Med J Aust 1991; 154:698-701.
37. Larrey D, Vial T, Micaleff A, Babany G, Morichau-Beauchant M, Michel M, Benhamou JP. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992; 33:368-371.
38. Silvain C, Fort E, Levillain P, Labat-Labourdette J, Beauchant M. Granulomatous hepatitis due to combination of amoxycillin and clavulanic acid. Dig Dis Sci 1992; 37:150-152.
39. Hebbard GS, Smith KG, Gibson PR, Bathal PS. Augmentin-induced jaundice with a fatal outcome. Med J Aust 1992; 156:285-286.
40. Ragg M. MaLAM (International and Australia) and Augmentin. Lancet 1993; 342:487.
41. ADRAC. Drug-induced cholestatic hepatitis from common antibiotics. Med J Aust 1992; 157:531.
42. Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, Druez P, Omar M, Kockx M, Hubens H, Haber I, Rahier J, Geubel AP. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995; 22:71-77.
43. Kando JC, Yonkers AK, Cole OJ. Gender as a risk factor for adverse events to medications. Drugs 1995; 50:1-6.
44. Thomson JA, Fairley CK, Ugoni AM, Forbes AB, Purcell PM, Desmond PV, Smallwood RA, Mc Neil JJ. Risk factors for the development of amoxycillin-clavulanic acid-associated jaundice. Med J Aust 1995; 162:638-640.
45. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United Kingdom. JAMA 1995; 273:214-217.
46. Ryley NG, Fleming KA, Chapman RW. Focal destructive cholangiopathy associated with amoxycillin/clavulanic acid (Augmentin). J Hepatol 1995; 23:278-282.
47. Nathani MG, Mutchnick MG, Tynes DL, Ehrinpreis MN. An unusual case of amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol 1998; 93:1363-1365.
48. Limauro DL, Chan-Tompkins NH, Carter RW, Brodmerkel GJ, Agrawal RM. Amoxicillin/clavulanate hepatic failure with progression to Stevens-Johnson syndrome. Ann Pharma-cother 1999; 33:560-564.
49. Stiegbauer KT, Smith C, Snoyer DC. The histological features of amoxicillin/clavulanic acid-induced hepatotoxicity. Hepathology 1994; 20:190A.
50. Hautekeete ML, Horsmans Y, Van Wayenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J, Geubel AP. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999; 117:1181-1186.
51. Bolton GC, Allen GD, Davies BE, Filer C, Jeffery DJ. The disposition of clavulanic acid in man. Xenobiotica 1986; 16:853-863.
52. Eliopoulos GM, Moellering RC. Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins. Ann Intern Med 1982; 97:755-760.
53. Parry MF. Toxic and adverse reactions encountered with new betalactam antibiotics. Bull NY Acad Med 1984; 60:358-368.
54. Drusano GL, Schimpff SC, Hewitt WL. The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis 1984; 6:13-32.
55. Kuye O, Teal J, DeVries VG, Morrow CA, Tally FP. Safety profile of piperacillin/tazobactam in phase I and III clinical trial studies. J Antimicrob Chemother 1993; 31(suppl A):113-124.
56. Sanders WE, Sanders CC. Pipercillin/tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996; 22:107-123.
57. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990; 88(suppl 4A):38S-44S.
58. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins: an update. Drug Safety 1993; 9:132-142.
59. Amman R, Neftel K, Hardmeier TH, Reinhardt M. Cephalosporin-induced cholestatic jaundice. Lancet 1982; 2:336-337.
60. Bosio M. Cholestatic jaundice and hematuria due to hypersensibility to cefaclor in a child. J Toxicol Clin Toxicol 1983; 20:79-84.
61. Eggleston SM, Belandres MM. Jaundice associated with cephalosporin therapy. Drug Intell Clin Pharm 1985; 19:553-555.
62. Stricker BH. Drug-Induced Hepatic Injury 2nd ed. Amsterdam: Elsevier, 1992.
63. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin. Am J Med 1985; 78(suppl 6A):73-78.
64. Arnaud M, Rochet N, Bonnet C, Deblois P, Bertin P, Treves R, Desproges-Gotteron R. Jaundice secondary to treatment with imipenem. Therapie 1990; 45:70.
65. Henry SA, Bendush CB. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Am J Med 1985; 78(suppl 2A):57-64.
66. Alvan G, Nord CE. Adverse effects of monobactams and carbapenems. Drug Safety 1995; 12:305-313.
67. Tolman KG, Sannela JJ, Freston JW. Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 1974; 81:58-60.
68. Zimmerman HJ, Maddley WC. Drug-induced hepatotoxicity. In: L Schiff, ER Schiff (eds). Diseases of the Liver. 6th ed. Philadelphia: JP Lippincott, 1987.
69. Viteri AL, Greene JF, Dyck WP. Erythromycin ethylsuccinate-induced cholestasis. Gastroenterology 1979; 76:1007-1008.
70. Keefe EB, Reis TC, Berland JE. Hepatotoxicity to both erythromycin estolate and erythromycin ethylsuccinate. Dig Dis Sci 1982; 27:701-704.
71. Diehl AM, Latham P, Boitnott JK, Mann J, Maddrey WC. Cholestatic hepatitis from erythromycin ethylsuccinate. Am J Med 1984; 76:931-934.
72. Inman WH, Rawson NS. Erythromycin estolate and jaundice. Br Med J 1983; 286:1954-1955.
73. Avila P, Capella D, Laporte JR, Moreno V. Which salt of erythromycin is most hepatotoxic? Lancet 1988; 1:1104.
74. Derby LE, Jick H, Henry DA, Dean AD. Erythromycin-associated cholestatic hepatitis. Med J Aust 1993; 158:600-602.
75. Carson JL, Strom BL, Duff A, Gupta A, Shaw M, Lundin FE, Das K. Acute liver disease with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 1993; 119:576-583.
76. Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16(suppl A):181-194.
77. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1973; 119:300-306.
78. Gholson CF, Warren CH. Fulminant hepatic failure associated with intravenous erythromycin lactobionate. Arch Intern Med 1990; 150:215-216.
79. Zafrani ES, Ishak KG, Rudzki C. Cholestatic and hepatocellular injury associated with erythromycin esters: report of nine cases. Dig Dis Sci 1979; 24:385-396.
80. Gafter U, Mandel E, Weiss S, Djaldetti M. Erythromycin estolate-induced hepatitis: ultrastructural study of the liver. NY State J Med 1979; 20:87-89.
81. Geubel AP, Nakad A, Rahier J, Dive C. Prolonged cholestasis and disappearance of interlobular bile ducts following chlorpropamide and erythromycin ethylsuccinate: case of drug interaction? Liver 1988; 8:350-353.
82. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A, Potet F, Benhamou JP. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15:244-251.
83. Young RA, Gonzales JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989; 37:8-41.
84. Dubois A, Nakache N, Faffanel C, Balmes JL. Hepatite aigue cholestatique apres prise de roxithromycine. Gastroenterol Clin Biol 1989; 13:317-318.
85. Delcourt A, Lambert M, Brenard R, Geubel A. Reversible liver injury possibly due to roxithromycin. Acta Clin Belg 1990; 45:206.
86. Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44:117-164.
87. Wallace RJ Jr., Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993; 16:215-221.
88. Yew WW, Chau CH, Lee J, Leung CW. Cholestatic hepatitis in a patient who received clarithromycin therapy for a Mycobacterium chelonae lung infection (letter). Clin Infect Dis 1994; 18:1025-1026.
89. Brown BA, Wallace RJ, Griffith DE, Girard W. Clarithromycin-induced hepatotoxicity (letter). Clin Infect Dis 1995; 20:1073-1074.
90. Viluksela M, Hanhijarvi H, Husband RF, Kosma VM, Collan Y, Mannisto PT. Comparative liver toxicity of various erythromycin derivatives in animals. J Antimicrob Chemother 1988; 21(suppl D):9-27.
91. Lehtonen L, Lankinen KS, Wikberg R, Rita H, Salmi HA, Valtonen V. Hepatic safety of erythromycin acistrate in 1549 patients with respiratory tract or skin infections. J Antimicrob Chemother 1991; 27:233-242.
92. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 1991; 91(suppl 3A): 40S-45S.
93. Garey KW, Amsden GW. Intravenous azithromycin. Ann Pharmacother 1999; 33:218-228.
94. Sides GD, Conforti PM. Safety profile of dirithromycin. J Antimicrob Chemother 1993; 31(suppl C):175-185.
95. See A, Weiffenbach E, Bouvry M. Cholestase au cours d’un traitement par la josamycine. Rev Med Interne 1986; 7:309-310.
96. Ponge A, Van Wasenhowe L, Ponge T, Cottin S. Hepatite au cours d’un traitement par la josamycine (letter). Rev Med Interne 1987; 8:117.
97. Dujovne CA. Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. Biochem Pharmacol 1978; 27:1926-1930.
98. Kendler J, Anuras S, Laborda O, Zimmerman HJ. Perfusion of the isolated rat liver with erythromycin estolate and other derivatives. Proc Soc Exp Biol Med 1972; 139:1272-1275.
99. Gaeta GB, Utili R, Adinolfil E, Abernathy CO, Guisti G. Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver. Toxicol Appl Pharmacol 1985; 80:185-192.
100. Larrey D, Funck Brentano C, Breil P, Vitaux J, Theodore C, Babany G, Pessayre D. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983; 32:1063-1068.
101. Zhang XJ, Thomas PE. Erythromycin as a specific substrate for cytochrome P450 3A isoenzymes and identification of a high affinity erythromycin V-demethylase in adult female rats. Drug Metab Dispos 1996; 24:23-27.
102. Larrey D, Tinel M, Pessayre D. Formation of inactive cytochrome P-450 Fe(II)-metabolite complexes with several erythromycin derivatives but not with josamycin and midecamycin in rats. Biochem Pharmacol 1983; 32:1487-1493.
103. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23:106-131.
104. Von Rosenstiel NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 1995; 13:105-122.
105. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, Pessayre D. Effects of clarithromycin on cytochrome P-450: comparison with other macrolides. J Pharmacol Exp Ther 1989; 250:746-751.
106. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D. Oxidative metabolism of clarithromycin in the presence of human liver microsomes: major role for the cytochrome P 450 3A (CYP 3A) subfamily. Drug Metab Dispos 1997; 25:623-630.
107. Delaforge M, Jaouen M, Mansuy D. Dual effects of macrolide antibiotics on rat liver cytochrome P 450. Induction and formation of metabolite-complexes: a structure-activity relationship. Biochem Pharmacol 1983; 32:2309-2318.
108. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimi-crob Agents Chemother 1991; 35:1186-1190.
109. Lindstrom TD, Hanssen BR, Wrighton SA. Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers. Antimicrob Agents Chemother 1993; 37:265-269.
110. Sartori E, Delaforge M, Mansuy D. In vitro interaction of rat liver cytochromes P-450 with erythromycin, oleandomycin and erythralosamine derivatives. Importance of structural factors. Biochem Pharmacol 1989; 38:2061-2068.
111. Fries J, Siraganian R. Sulfonamide hepatitis: report of a case due to sulfamethoxazole. N Engl J Med 1966; 274:95.
112. Dujovne CA, Chan CH, Zimmerman HJ. Sulfonamide hepatic injury. Review of the literature and report of a case due to sulfamethoxazole. N Engl J Med 1967; 277:785-788.
113. Tonder M, Nordoy A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol 1974; 9:93-96.
114. Colucci CF, Cicero ML. Hepatic necrosis and trimethoprim-sulfamethoxazole. JAMA 1975; 233:952-953.
115. Stevenson DK, Christie DL, Haas JE. Hepatic injury in adult caused by trimethoprimsulfamethoxazole. Pediatrics 1978; 61:864-866.
116. Brockner J, Boisen E. Fatal multisystemic toxicity after cotrimoxazole. Lancet 1978; 1:831.
117. Nair SS, Kaplan JM, Levine LH, Geraci K. Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis. Ann Intern Med 1980; 92:511-512.
118. Steward DL, Johnson RC. Acute hepatitis caused by sulfamethoxazole-trimethoprim. Gastroenterology 1980; 78:1323.
119. Ogilvie AL, Toghill PJ. Cholestatic jaundice due to cotrimoxazole. Postgrad Med J 1980; 56:202-204.
120. Abi-Mansur P, Ardiaca MC, Allam C. Trimethoprim-sulfamethoxazole-induced cholestasis. Am J Gastroenterol 1981; 76:356-359.
121. Coto H, McGowan WR, Pierce EH, Thomas E. Intrahepatic cholestasis due to trimethoprimsulfamethoxazole. South Med J 1981; 74:897-898.
122. Ransohoff DF, Jacobs G. Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. Gastroenterology 1981; 80:816-819.
123. Ghishan FK. Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis. Clin Pediatr 1983; 22:212-214.
124. Thies PW, Dull WL. Trimethoprim-sulfamethoxazole-induced cholestatic hepatitis: inadvertent rechallenge. Arch Intern Med 1984; 144:1691-1692.
125. Munoz SJ, Marinez-Hernandez A, Maddrey WC. Intrahepatic cholestasis and phospholip-idosis associated with the use of trimethoprim-sulfamethoxazole. Hepatology 1990; 12:342-347.
126. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim-sulfamethoxazole. Gastroenterology 1992; 102:2148-2150.
127. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978; 75:95-99.
128. Callen JP, Soderstrom RM. Granulomatous hepatitis associated with salicylazosulfapyridine therapy. South Med J 1978; 1159-1160.
129. Lozek JD, Werlin SL. Sulfasalazine hepatotoxicity. Am J Dis Child 1981; 135:1070-1071.
130. Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and neurotoxicity following sulfasalazine administration. Aust NZ J Med 1982; 12:76-80.
131. Koch-Weser J, Hodel C, Leimer R, Styk S. Adverse reactions to pyrimethamine/sulfadoxine. Lancet 1982; 2:1459.
132. Olsen VV, Loft S, Christensen KD. Serious reactions during malaria prophylaxis with pyrimethamine-sulfadoxine. Lancet 1982; 2:994.
133. Lazar HP, Murphy RL, Phair JP. Fansidar and hepatic granulomas. Ann Intern Med 1985; 102:722.
134. Selby CD, Ladussans EJ, Smith PG. Fatal multisystemic toxicity associated with prophylaxis with pyrimethamine and sulfadoxine (Fansidar). Br Med J 1985; 290:113-114.
135. Zitelli BJ, Alexander J, Taylor S, Miller KD, Howrie DL, Kuritsky JN, Perez TH, Van Thiel DH. Fatal hepatic necrosis due to pyrimethamine-sulfadoxine (Fansidar). Ann Intern Med 1987; 106:393-395.
136. Farrell GC. Drug-Induced Liver Disease. Edinburgh: Churchill Livingstone, 1994.
137. Beard K, Belic L, Aselton P, Perera D, Jick H. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986; 26:633-637.
138. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim-sulfamethoxazole. Am J Gastroenterol 1994; 89:1230-1234.
139. Carr A, Tindall B, Penny R, Cooper DA. Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993; 7:1532-1533.
140. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD, Slattery JT. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin Pharmacol Ther 1996; 59:332-340.
141. Cribb AE, Spielberg SP. Hepatic microsomal metabolism of sulfamethoxazole to the hydroxylamine. Drug Metab Dispos Biol Fate Chem 1990; 18:784-787.
142. Cribb AE, Spielberg SP. Sulfamethoxazole is metabolized to the hydroxylamine in humans. Clin Pharmacol Ther 1992; 51:522-526.
143. Vree TB, Van der Ven AJ, Koopmans PP, VanEwijk-Beneken Kolmer EW, Verwey-Van Missen CP. Pharmacokinetics of sulfamethoxazole with its hydroxy metabolites and N-4-acetyl-glucuronide, N1-glucuronide conjugates in healthy volunteers. Clin Drug Invest 1994; 9:43-53.
144. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Synthesis and in vitro toxicity of hydroxylamine metabolites of the sulfonamides. J Pharmacol Exp Ther 1988; 244:724-728.
145. Pirmohamed M, Coleman MD, Hussain F, Breckenridge AM, Park BK. Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes. Br J Clin Pharmacol 1991; 32:303-310.
146. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37:25-79.
147. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991; 49:13-17.
148. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is a risk factor for sulfonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255-258.
149. Das KM, Eastwood MA, McManus JP, Sircus WA. Adverse reactions during salicylazosulfa-pyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289:491-495.
150. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179-184.
151. Rieder MJ, Uetrecht J, Shear NH, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in vitro rechallenge with hydroxylamine metabolites. Ann Intern Med 1989; 110:286-289.
152. Rieder MJ. Mechanisms of unpredictable adverse drug reactions. Drug Safety 1994; 11:196-212.
153. Tanner AR. Hepatic cholestasis induced by trimethoprim. Br Med J 1986; 293:1072-1073.
154. Dossing M, Andreasen PB. Drug-induced liver disease in Denmark: an analysis of 572 cases of hepatotoxicity reported to the Danish board of adverse reactions to drugs. Scand J Gastroenterol 1982; 17:205-211.
155. Winston DJ, Lau WK, Gale RP, Young LS. Trimethoprim-sulfamethoxazole for the treatment of Pneumocystis carinii pneumonia. Ann Intern Med 1980; 92:762-769.
156. Van der Ven AJ, Koopmans PP, Vree TB, Van der Meer JW. Adverse reactions to cotrimox-azole in HIV infection. Lancet 1991; 338:431-433.
157. Caar A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency virus (HIV) infection. J Clin Immunol 1991; 11:55-64.
158. Hughes WT, Lafon SW, Scott JD, Masur H. Adverse events associated with trimethoprimsulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995; 171:1295-1301.
159. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 495-499.
160. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1987; 9(suppl 2):S184-191.
161. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988; 109:280-287.
162. Kaufmann GR, Wenk M, Taeschner W, Peterli B, Gyr K, Meyer KA, Haefeli WE. N-Acetyl-transferase-2 polymorphism in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1996; 60:62-67.
163. Smith CL, Brown I, Torraca BM. Acetylator status and tolerance of high dose trimethoprimsulfamethoxazole therapy among patients infected with human immunodeficiency virus. Clin Infect Dis 1997; 25:1477-1478.
164. Droge W. Cysteine and glutathione deficiency in AIDS patients: a rationale for the treatment with N-acetylcysteine. Pharmacology 1993; 46:61-65.
165. Lee BL, Wong D, Benowitz NL, Sullam PM. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther 1993; 53:529-535.
166. O’Neil WM, Gilfix BM, Digirolano A, Tsoukas CM, Wainer IW. N-Acetylation among HIVpositive patients and patients with AIDS: when is fast, fast and slow, slow? Clin Pharmacol Ther 1997; 62:261-271.
167. Delomenie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-aigrin E, Rozenbaum W, Krishnamoorthy R, Dupret JM. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients (letter). Br J Clin Pharmacol 1994; 38:581 - 582.
168. Hofstede HJ, Van der Ven AJ, Koopmans PP. Drug reactions to cotrimoxazole in HIV infection: Possibly not due to the hydroxylamine metabolites of sulphamethoxazole (letter). Br J Clin Pharmacol 1999; 47:571-573.
169. Staal FJ, Ela SW, Roedere M, Anderson MT, Herzenberg LA. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992; 339:909-912.
170. Van der Ven AJ, Vree TB, Kolmer EW, Koopmans PP, Van der Meer JW. Urinary recovery and kinetics of sulphamethoxazole and its metabolites in HIV-seropositive patients and healthy volunteers after a single oral dose of sulphamethoxazole. Br J Clin Pharmacol 1995; 39:621-625.
171. Pirmohamed M, Williams D, Tingle MD, Barry M, Khoo SH, O’Mahony C, Wilkins EG, Breckenridge AM, Park BK. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996; 10:501-507.
172. Carr A, Swanson C, Penny R. Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993; 167:180-185.
173. Burette A, Finet C, Prigogine T, De Roy G, Deltenre M. Acute hepatic injury associated with minocycline. Arch Intern Med 1984; 144:1491-1492.
174. Riely CA. Acute fatty liver of pregnancy. Semin Liver Dis 1987; 7:47-54.
175. Combes B, Whalley DJ, Adams RH, et al. Tetracycline and the liver: clinical manifestations of tetracycline toxicity. Prog Liver Dis 1972; 4:589-596.
176. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107:1844-1847.
177. Freneaux E, Labbe G, Letteron P, Le Dinh T, Degott C, Geneve J, Larrey D, Pessayre D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: Possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988; 8:1056-1062.
178. Davies MG, Kersey PJ. Acute hepatitis and exfoliative dermatitis associated with minocycline. Br Med J 1989; 298:1523-1524.
179. Min DI, Burke PA, Lewis D, Jenkins RL. Acute hepatic failure associated with oral minocycline: a case-report. Pharmacotherapy 1992; 12:68-71.
180. Boudreaux JP, Hayes DH, Mizrahi S, et al. Fulminant hepatic failure, hepatorenal syndrome and necrotizing pancreatitis after minocycline hepatotoxicity. Trans Proc 1993; 25:1073.
181. Kaufmann D, Pichler W, Beer JH. Severe episodes of high fever with rash, lymphadenopathy, neutropenia and eosinophilia after minocycline therapy for acne. Arch Intern Med 1994; 154: 1983-1984.
182. Knowles SR, Shapiro L, Shear NH. Serious adverse reaction induced by minocycline. Arch Dermatol 1996; 132:934-939.
183. Malcolm A, Heap TR, Eckstein RP, Lunzer MR. Minocycline-induced liver injury. Am J Gastroenterol 1996; 91:1641-1643.
184. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline-induced autoimmune hepatitis and systemic lupus erythematus-like syndrome. Br Med J 1996; 312:169-172.
185. Golstein PE, Deviere J, Cremer M. Hepatitis and drug-related lupus induced by minocycline treatment. Am J Gastroenterol 1997; 92:143-146.
186. Bhat G, Jordan J, Sokalski S, Bajaj V, Marshall R, Berlelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol 1998; 27:74-75.
187. Lopez-Navidad A, Domingo P, Cadafalch J, Farrerons J. Norfloxacin-induced hepatotoxicity. J Hepatol 1990; 11:277-278.
188. Blum A. Ofloxacin-induced acute severe hepatitis (letter). South Med J 1991; 84:1158.
189. Grassmick BK, Lehr VT, Sundareson AS. Fulminant hepatic failure possibly related to ciprofloxacin. Ann Pharmacother 1992; 26:636-639.
190. Levinson JR, Kumar A. Ciprofloxacin-induced cholestatic jaundice: a case-report (abstract). Am J Gastroenterol 1993; 88:1619.
191. Fuchs S, Simon Z, Brezin M. Fatal hepatic failure associated with ciprofloxacin. Lancet 1994; 34:738-739.
192. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: Past, present, and future. Drug Safety 1995; 13:343-358.
193. Villeneuve JP, Davies C, Cote J. Suspected ciprofloxacin-induced hepatotoxicity. Ann Pharmacother 1995; 29:257-259.
194. Jick SS, Jick H, Dean AD. A follow-up safety study of ciprofloxacin users. Pharmacotherapy 1993; 13:461-464.
195. Arcieri GM, Becker N, Esposito B, Griffith E, Heyd A, Neumann C, O’Brien B. Safety of intravenous ciprofloxacin: a review. Am J Med 1989; 87(suppl 5A):92S-97S.
196. Schacht P, Hullmann R. Safety of oral ciprofloxacin: an update based on clinical trial results. Am J Med 1989; 87(suppl 5A):98S-102S.
197. Corrado ML, Struble WE, Peter C, Hoagland V, Sabbaj J. Norfloxacin: a review of safety studies. Am J Med 1987; 82(suppl 6B):22-26.
198. Halkin H. Adverse effects of the fluoroquinolones. Rev Infect Dis 1988; 10(suppl 1):S258-S261.
199. Dembry LM, Farrington JM, Andriole VT. Fluoroquinolone antibiotics: adverse effects and safety profile. Infect Dis Clin Pract 1999; 8:421-428.
200. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988; 8:599-606.
201. Klemola H, Penttila L, Runeberg L. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975; 10:501-505.
202. Hatoff DE, Cohen M, Schweigert BF, Talbret WM. Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med 1979; 67:117-121.
203. Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease: clinical course and outcome of five cases. Scand J Gastroenterol 1979; 14:497-502.
204. Sharp J, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980; 92:14-19.
205. Tolman KG. Nitrofurantoin and chronic active hepatitis. Ann Intern Med 1980; 92:119-120.
206. Mollison LC, Angus P, Richards M, Jones R, Ireton J. Hepatitis due to nitrofurantoin. Med J Aust 1992; 156:347-349.
207. Golstein LI, Ishak KG, Burns W. Hepatic injury associated with nitrofurantoin therapy. Am J Dig Dis 1974; 19:987-989.
208. Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992; 87:891-893.
209. Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975; 135:733-735.
210. Mackay IR, Tait BD. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology 1980; 72:95-98.
211. Moreno SN, Mason RP, Docampo R. Reduction of nifurtimox and nitrofurantoin to free radical metabolites by rat liver mitochondria: evidence of an outer membrane-located nitroreductase. J Biol Chem 1984; 259:6298-6305.
212. Lim LO, Bortell R, Neims AH. Nitrofurantoin inhibition of mouse liver mitochondrial respiration involving NAD-linked substrates. Toxicol Appl Pharmacol 1986; 84:493-499.
213. Capelle P, Dhumeaux D, Mora M, Feldman G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972; 13:366.
214. Emerit J, Decroix G, Chomette G, Perie C, Pessayre D. Données nouvelles sur les hépatites observées au cours des traitements antituberculeux incluant la rifampicin. Rev Fr Mal Respir 1974; 2:565-584.
215. Durand F, Jebrak G, Pessayre D, Fournier M, Bernuau J. Hepatotoxicity of antitubercular treatments. Drug Safety 1996; 15:394-405.
216. Steele MA, Burk RF, Des Prez RM. Toxic hepatitis with isoniazid and rifampicin: a metaanalysis. Chest 1991; 99:465-471.
217. Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4:83-113.
218. Beever IW, Blair IA, Brodie MJ. Circulating hydrazine during treatment with isoniazidrifampicin in man. Br J Clin Pharmacol 1982; 13:599P.
219. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampicin-induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986; 133:1072-1075.
220. Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132-136.
221. Gronhagen-Riska C, Hellstrom E, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978; 118:461-466.
222. Mitchell I, Wendon J, Fitt S, Williams R. Antituberculous therapy and acute liver failure. Lancet 1995; 345:555-556.
223. Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculous drugs. Thorax 1996; 51: 111-113.
224. Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci 1972; 263:369-382.
225. Elmore M, Rissing JP, Rink L, Brooks GF. Clindamycin-associated hepatotoxicity. Am J Med 1974; 57:627-630.
226. Gray JE, Weaver RN, Bollert JA, Feenstra ES. The oral toxicity of clindamycin in laboratory animals. Toxicol Appl Pharmacol 1972; 21:516-522.
227. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-329.
228. Perfect JR, Lindsay MH, Drew RH. Adverse drug reactions to systemic antifungals: Prevention and management. Drug Safety 1992; 7:323-363.
229. Carnecchia BM, Kurtzke JF. Fatal toxic reaction to amphotericin B in cryptococcal meningoencephalitis. Ann Intern Med 1960; 53:1027-1036.
230. Miller MA. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J 1984; 131:1245-1247.
231. Gill J, Sprenger HR, Ralph ED, Sharpe MD. Hepatotoxicity possibly caused by amphotericin B. Ann Pharmacother 1999; 33:683-685.
232. Garcia Rodriguez LA, Duque A, Castellsague J, Perez-Gutthann S, Stricker BH. A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs. Br J Clin Pharmacol 1999; 48:847-852.
233. Petersen EA, Alling DU, Kirkpatrick CH. Treatment of chronic cutaneous candidiosis with ketoconazole: a controlled clinical trial. Ann Intern Med 1980; 93:791-795.
234. Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole treatment. Br Med J 1981; 283:825-826.
235. Mc Nair AL, Gascoigne E, Heap J, Schuermans V, Symoens J. Hepatitis and ketoconazole therapy. Br Med J 1981; 283:1058.
236. Firebrace DA. Hepatitis and ketoconazole therapy. Br Med J 1981; 283:1058-1059.
237. Horsburgh CR, Kirkpatrick CH, Teutsch CB. Ketoconazole and the liver. Lancet 1982; 1:860.
238. Svejgaard E, Ranek L. Hepatic dysfunction and ketoconazole therapy. Ann Intern Med 1982; 96:788-789.
239. Pegram PS, Kerns FT, Wsilauskas BL, Hampton KD, Scharyj M, Burke JG. Successful keto-conazole treatment of protothecosis with ketoconazole-associated hepatotoxicity. Arch Intern Med 1983; 143:1802-1805.
240. Rollman O, Loof L. Hepatic toxicity of ketoconazole. Br J Dermatol 1983; 143:376-378.
241. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. Gastroenterology 1984; 86:503-13.
242. Svedhem A. Toxic hepatitis following ketoconazole treatment. Scand J Infect Dis 1984; 16: 123-125.
243. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. Arch Intern Med 1984; 144:1069-1070.
244. Bercoff E, Bernuau J, Degott C, Kalis B, Lemaire A, Tilly H, Rueff B, Benhamou JP. Keto-conazole-induced fulminant hepatitis. Gut 1985; 26:636-638.
245. Stricker BH, Block AP, Bronkhorst FB, Vanparys GE, Desmet VJ. Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases. J Hepatol 1986; 3:399-406.
246. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 1987; 294:419-422.
247. Van Parys G, Evenepoel C, Van Damme B, Desmet VJ. Ketoconazole-induced hepatitis: a case with definite cause-effect relationship. Liver 1987; 7:27-30.
248. Benson GD, Anderson PK, Burton C, Ishak KG. Prolonged jaundice following ketoconazole-induced hepatic injury. Dig Dis Sci 1988; 33:240-246.
249. Knight TE, Shikuma CY, Knight J. Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. J Am Acad Dermatol 1991; 25:398-400.
250. Klausner MA. Ketoconazole and hepatitis. J Am Acad Dermatol 1992; 26:1028-1029.
251. Chien RN, Yang LJ, Lin PY, Liaw YF. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology 1997; 25:103-107.
252. Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993; 29:S50-S54.
253. Franklin JM, Elias E, Hirsch C. Fluconazole induced jaundice. Lancet 1990; 336:565.
254. Munoz P, Moreno S, Berenguer J, Bernaldo de Quiros JL, Bouza E. Fluconazole related hepatotoxicity in patients with acquired immunodeficiency syndrome. Arch Intern Med 1991; 151:1020-1021.
255. Wells C, Lever AM. Dose-dependent fluconazole hepatotoxicity proved on biopsy and rechallenge. J Infect 1992; 24:111-112.
256. Gearhart MO. Worsening of liver function with fluconazole and review of azole antifungal hepatotoxicity. Ann Pharmacother 1994; 28:1117-1181.
257. Trujillo MA, Galgiani JN, Sapllner RF. Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med 1994; 154:102-104.
258. Guillaume MP, De Prez C, Cogan E. Subacute mitochondrial liver disease in a patient with AIDS: Possible relationship to prolonged fluconazole administration. Am J Gastroenterol 1996; 91:165-168.
259. Jacobson MA, Hanks DK, Ferrell LD. Fatal acute hepatic necrosis due to fluconazole Am J Med 1994; 96:188-190.
260. Bronstein JA, Gros P, Hernandez E, Larroque P, Molinie C. Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997; 25:1266-1267.
261. Tucker RM, Haq Y, Denning DW, Stevens DA. Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother 1990; 26:561-566.
262. Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37:310-344.
263. Lavrijsen AP, Balmus KJ, Nugteren Huying WM, Roldaan AC, van’t Wout JW, Stricker BH. Hepatic injury associated with itraconazole. Lancet 1992; 340:251-252.
264. Gallardo-Quesada S, Luelmo-Aguilar J. Hepatotoxicity associated with itraconazole. Int J Dermatol 1995; 34:589.
265. Hall M, Monka C, Krupp P, O’Sullivan D. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol 1997; 133:1213-1219.
266. Lowe G, Gren C, Lennings P. Hepatitis associated with terbinafine treatment. Br Med J 1993; 306:248.
267. Van’t Wout LW, Herrmann WA, de Vries RA, Stricker BH. Terbinafine-associated hepatic injury. J Hepatol 1994; 21:115-117.
268. Lazaros GA, Papatheodoridis GV, Delladetsima JK, Tassopoulos NC. Terbinafine induced cholestatic liver disease. J Hepatol 1996; 24:753-756.
269. Balfour JA, Faulds D. Terbinafine. A review of its pharmacodynamic and pharmaco-kinetic properties, and therapeutic potential in superficial mycosis. Drugs 1992; 43:259-284.
270. Record CO, Skinner JM, Sleight P, Speller DC. Candida endocarditis treated with 5-fluoro-cytosine. Br Med J 1971; 1:262-264.
271. Chiprut RO, Viteri A, Jamroz C, Dyck WP. Intrahepatic cholestasis after griseofulvin administration. Gastroenterology 1976; 70:1141-1143.